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Abstract
Background: Mutations in Plasmodium falciparum that confer resistance to first-line antimalarial
drugs have spread throughout the world from a few independent foci, all located in areas that were
likely characterized by low or unstable malaria transmission. One of the striking differences
between areas of low or unstable malaria transmission and hyperendemic areas is the difference in
the size of the population of immune individuals. However, epidemiological models of malaria
transmission have generally ignored the role of immune individuals in transmission, assuming that
they do not affect the fitness of the parasite. This model reconsiders the role of immunity in the
dynamics of malaria transmission and its impact on the evolution of antimalarial drug resistance
under the assumption that immune individuals are infectious.
Methods: The model is constructed as a two-stage susceptible-infected-susceptible (SIS) model of
malaria transmission that assumes that individuals build up clinical immunity over a period of years.
This immunity reduces the frequency and severity of clinical symptoms, and thus their use of drugs.
It also reduces an individual's level of infectiousness, but does not impact the likelihood of becoming
infected.
Results: Simulations found that with the introduction of resistance into a population, clinical
immunity can significantly alter the fitness of the resistant parasite, and thereby impact the ability
of the resistant parasite to spread from an initial host by reducing the effective reproductive
number of the resistant parasite as transmission intensity increases. At high transmission levels,
despite a higher basic reproductive number, R0, the effective reproductive number of the resistant
parasite may fall below the reproductive number of the sensitive parasite.
Conclusion: These results suggest that high-levels of clinical immunity create a natural ecological
refuge for drug-sensitive parasites. This provides an epidemiological rationale for historical patterns
of resistance emergence and suggests that future outbreaks of resistance are more likely to occur
in low- or unstable-transmission settings. This finding has implications for the design of drug policies
and the formulation of malaria control strategies, especially those that lower malaria transmission
intensity.
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Background
Malaria is the leading cause of death in children under five
in sub-Saharan Africa [1]. Prompt treatment with effective
antimalarial drugs could prevent much of the morbidity
and mortality associated with clinical malaria, but the
evolution of resistance has diminished the therapeutic
efficacy of two previous first-line antimalarials, chloro-
quine (CQ) and sulphadoxine-pyrimethamine (SP). His-
torically, it has been suggested that resistance to both CQ
and SP emerged from a limited number of de novo selec-
tion events in areas of low or unstable transmission [2,3].
Genetic evidence suggests that most CQ-resistant parasites
in the world today are descended from one of four
founder events [4,5] that occurred in Southeast Asia,
South America and Papua New Guinea, and then spread
to other regions, including sub-Saharan Africa. Evidence
also suggests that resistance to SP originated from only a
few foci [6-8]. Several hypotheses about the de novo muta-
tion rate and the selection pressure resistant parasites face
and their relation to transmission intensity have been pro-
posed to explain why CQ resistance originated in what is
presumed to be low or unstable transmission areas out-
side of sub-Saharan Africa, including (a) a lower fre-
quency of resistant alleles in higher transmission areas
because of within-host competition [9]; (b) less drug
treatment (per parasite) in higher transmission areas
[2,9,10]; and (c) a lower frequency of selfing in higher
transmission areas, which increases the probability that
multilocus resistant genotypes will be broken up by the
action of Mendelian segregation [9,11,12]. An additional
explanation is that in high transmission areas, where
immunity is better developed, mutant parasites are less
likely to survive a host immune response [10,13].
Although the evolution of resistant parasites within a sin-
gle host is a significant risk factor for the emergence of
resistance within a population, the effectiveness of an
antimalarial drug is affected only if these resistant para-
sites spread, a process that is driven both by the overall
rate of transmission and by the relative fitness of drug-
resistant and drug-sensitive parasites. Parasite fitness is
related to the population treatment rate and to the biolog-
ical cost of resistance. Because of differences in vector
ecology and biting preferences, transmission intensities
vary from less than one infectious bite per decade to more
than 1,000 per year [14], and the basic reproductive
number (R0) can exceed 3,000 [15]. Higher transmission
intensity is associated with a higher level of clinical immu-
nity to malaria – reduced frequency and severity of clinical
symptoms in older children and adults – which results in
a reduction in the need for antimalarial drugs [16-19].
Immunity to malaria has consequences for transmission
as well; blood-stage immunity reduces asexual parasite
and gametocyte densities in older children and adults
[20], and transmission-blocking immunity can block
development of the parasite in the mosquito [21]. Impor-
tantly, despite significant reductions in clinical symptoms
and infectiousness, older individuals still become infected
and remain infectious to mosquitoes, albeit at relatively
lower levels, even in holoendemic areas [22-24].
Even though immunity affects both the transmission
dynamics and treatment rates, epidemiological models
have generally assumed that immune individuals are not
infectious to mosquitoes, and thus do not contribute to
parasite fitness [20,25-27]. Consequently, an epidemio-
logical model for the spread of resistance found no differ-
ence in the ability of resistant parasites to spread at
different transmission rates [27], or why resistance to CQ
emerged outside of sub-Saharan Africa.
This paper reconsiders the role of immunity in the trans-
mission dynamics of malaria and its effect on the evolu-
tion of antimalarial drug resistance under the assumption
that immune individuals are infectious. Using a novel epi-
demiological model with two immune stages, nonim-
mune and clinically immune, the role of immunity in the
emergence of resistance is reexamined based on quantita-
tive effects associated with clinical immunity. Individuals
in the clinically immune stage have lower transmission,
lower incidence of clinical disease, and consequently a
lower rate of drug treatment. Based on the defined rela-
tionship between transmission intensity, immunity, and
clinical malaria, the model is used to explore the relation-
ship between vector ecology, human epidemiology, and
the ability of a resistant parasite to spread.
Methods
Individuals living in areas of endemic P. falciparum trans-
mission develop immunity to malaria with age [28] and
exposure [29,30]; immunity is manifest as a decline in
parasite densities (both trophozoites and gametocytes) in
the blood [20], a lower probability of transmission from
humans to mosquitoes [22,23], and a decline in the fre-
quency and severity of clinical malaria [16-19], though lit-
tle decline in the probability of becoming infected
[24,31]. Thus, it is assumed that individuals develop a
form of clinical immunity over time in which they are less
likely to infect mosquitoes or manifest clinical symptoms
but are no less likely to become infected.
The model is based on earlier models developed for the
Garki Project [20], in which individuals acquire immunity
after being infected for a period of time. However, the
number of infected classes was simplified and the
assumption that individuals develop full transmission-
blocking immunity was relaxed. As with the Garki model,
clinical immunity is incorporated as a second immune
stage in a susceptible-infected-susceptible (SIS) model.
Though, in this model clinically immune individualsMalaria Journal 2008, 7:67 http://www.malariajournal.com/content/7/1/67
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remain infectious to mosquitoes and infect mosquitoes
with lower probability; also, a smaller fraction of new
infections progress to clinical malaria. Clinical episodes of
malaria are important for the evolution of resistance
because individuals who develop clinical symptoms are
more likely to seek treatment; thus an increasing fre-
quency of clinical episodes is associated with increasing
drug pressure. Consequently, in this model clinically
immune individuals represent a refuge for drug-sensitive
pathogens because of lower treatment rates. The evolution
of resistance is incorporated by assuming that individuals
can be infected by either resistant or sensitive parasites.
Population dynamics
It is assumed that both nonimmune and clinically
immune individuals can be susceptible, infected with sen-
sitive parasites, or infected with resistant parasites. The
human population density in each state is denoted Si, Iwi,
Ixi, where the subscripts w and x denote infections with
drug-sensitive wild-type and resistant phenotypes, respec-
tively, and the i subscript denotes the immune stage. The
population size is normalized to one, and the population
birthrate B is set equal to the per capita death rate of the
human population, μ, so that the total population size
stays constant.
Entomology
Model notation follows Macdonald [32] and Smith and
McKenzie [33]; m denotes the number of mosquitoes per
human and a the human feeding rate (the number of bites
on humans per mosquito per day). The instantaneous
death rate is g (e-g is the probability of a mosquito surviv-
ing one day), and n is the number of days required for
sporogony. Vectorial capacity (V), the number of infec-
tious bites by a mosquito over its lifetime, is then given by
the formula V = ma2e-gn/g.
The fraction P of bites on humans that infect a mosquito
depends on the differing transmission intensities of the
two-stages, c1 and c2, and the number of humans in each
stage; thus P = c1(Iw1 + Ix1) + c2(Iw2 + Ix2). The sporozoite
rate, or the fraction of infectious mosquitoes, is aPe-gn/(g +
aP). The entomological inoculation rate (EIR), the
number of infectious bites per person per day, is calcu-
lated as the product of the human biting rate (ma) and the
sporozoite rate (aPe-gn/(g + aP)). The force of infection, or
happenings rate (h), is bEIR, where b, the infectivity rate,
measures the fraction of bites in humans that produce a
patent infection. It follows that h=(bVP)/(1 + sP), where s
= a/g is called the stability index, the number of bites on a
human per vector per lifetime. The fraction of infections
that are drug sensitive is Fw = (c1Iw1 + c2Iw2)/P and the frac-
tion that are drug resistant is Fx = (c1Ix1 + c2Ix2)/P. Happen-
ings rates for drug-sensitive and drug-resistant infections
are hw = Fwh and hx = Fxh, respectively.
Immunity acquisition and parasite clearance
Clinical immunity is assumed to develop in infected indi-
viduals after ten years. Once individuals gain immunity,
protection is retained through biting and is lost at a faster
rate (γ) than it is gained (θ). The values are based on a sig-
nificant number of age-prevalence studies suggesting that
children acquire immunity after approximately five to 10
years [29,30,34], and additional studies that suggest a
strong role of biting in maintaining immunity, and a loss
of immunity that occurs after exposure to infection is
eliminated [35]. Because not all infections result in fever
and other associated symptoms, it is assumed that clinical
symptoms arise in infected individuals at a rate σi and that
a fraction fi are treated and cleared of parasites. Thus, exist-
ing infections are cleared by drugs at the rate ρi = fiσi. It is
further assumed that a fraction of new infections ξi in sus-
ceptible individuals develop clinical symptoms and are
treated with drugs and cleared immediately prior to the
development of gametocytes, thus precluding the possi-
bility of transmission. In these individuals it is as if the
infection never occurred.
Mutations conferring resistance to antimalarial drugs are
likely to be disadvantageous to the parasite. For example,
resistance to CQ in P. falciparum has been shown to have
a fitness cost of approximately 25 percent in vitro [36] and
5 percent in vivo [37,38]. Although a fitness cost could
conceivably occur at any or all stages of the parasite life-
cycle, where it is implemented in this model is not partic-
ularly important for the transmission dynamics (though it
could be important in other models), so it is assumed that
resistant infections are cleared at a faster rate and therefore
transmit for a relatively shorter period. Thus, infections
clear naturally at rate rw when an individual is infected
with a drug-sensitive phenotype and rx for drug-resistant
infections.
Equations
Based on the above assumptions, model dynamics are
described by a simple set of coupled ordinary differential
equations:
 SBSI r I rS h h ww x x w x 12 1 1 1 11 1 =+ + + + − − + + gr xm () ( ( ) )
(1)
 IS h I r ww w w 11 1 1 1 1 =− −+ + + ()( ) xrq m (2)
 IS h I r xx x x 11 1 =− + + () qm (3)
 SI r I rS h h ww x x w x 22 2 2 2 2 1 =+ + − − + + + () ( ( ) ) rx g m
(4)
 IS h I I r ww w w w 22 2 1 2 2 1 =− + −+ + () ( ) xqr m (5)Malaria Journal 2008, 7:67 http://www.malariajournal.com/content/7/1/67
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A diagram of the model is found in Figure 1.
Results
The principal assumptions for the analysis were that
immune individuals are less infectious to mosquitoes (c2
<c1) and less likely to develop clinical malaria and get
treated (ρ2 < ρ1 and ξ2 < ξ1), and that parasites face a resist-
ance-related fitness cost (rx > rw). While recent evidence
has suggested that individuals with clinical-immunity
may recover at faster rates [39], it was assumed that recov-
ery from infection was independent of immune status in
the base model. Based on these assumptions, the equilib-
rium of the system was determined without resistance and
then the resulting spread of resistance was simulated
across a range of transmission rates (from less than one to
more than 600 infectious bites per person per year) using
a set of baseline assumptions (Table 1).
At equilibrium without resistance, the results were con-
sistent with other models of transmission. As vectorial
capacity increases, the proportion of the population that
is nonimmune, and thus subject to frequent attacks,
increases sharply and then slowly decreases, while the
proportion of immune individuals increases steadily until
it plateaus at a fairly high level (Figure 2). As expected
[24,31], the infected proportion of the population nears
100 percent at high transmission levels, though a signifi-
cant portion of infected individuals are clinically
immune. In addition, the results suggest that clinical epi-
sodes of malaria – a proxy for hospital admissions for
malaria as well as severe malaria – plateau at intermediate
levels of transmission, which is consistent with other
research [30].
Because symptomatic individuals are more likely to use
antimalarial drugs, the number of individuals experienc-
ing a clinical episode affects the transmission dynamics by
changing the drug pressure facing the parasite. Individuals
that acquire clinical immunity, have reduced rates of clin-
ical episodes [16-19], which reduces the rate of drug use.
Though individuals will continue to receive antimalarial
treatments throughout their lives, these treatments occur
less frequently as immunity increases, and often can be
unconnected to the peaks of parasitemia [3]. This reduc-
tion in the treatment rate reduces the resistance selection
pressure, providing a refuge for drug-sensitive parasites. In
previous epidemiological models of transmission, these
immune individuals were not assumed to have a signifi-
cant qualitative effect on the dynamics of the system,
 IS h I I r xx x x x 22 1 2 =+ − + qm () (6)
SIS two-stage model Figure 1
SIS two-stage model. Susceptible individuals (S) become infected (I) with wild-type infections at the rate hw(1-ξi) and resist-
ant infections at the rate hx, where hi is the happenings rate (see text) and ξi is the rate at which new infections result in clini-
cally manifested symptoms that are treated and resolved prior to the formation of gametocytes. Infected individuals naturally 
clear resistant infections at rate rxi, and they clear wild-type infections at the rate ρi+rwi, where ρi is the rate of drug treatment. 
Infected individuals acquire semi-immunity at rate θ and lose immunity at rate γ if they are no longer infected. Individuals die 
from all states at a background rate of μ and are born at rate B as nonimmune susceptibles (process not shown).
S1
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because young children were assumed to dominate trans-
mission events [25]. However, clinically immune individ-
uals are infectious and can significantly affect the
dynamics of transmission when the distribution between
sensitive and resistant infections is different in nonim-
mune and clinically immune individuals.
Distributional differences in the frequencies of infection
types are driven by drug treatment rates, and these differ-
ences can be calculated as differences in the relative fitness
of resistant parasites compared with sensitive parasites.
Parasite fitness was calculated as the basic reproductive
number (R0) of both the resistant and the sensitive para-
sites when the population is completely naïve (sub-
scripted by 1) and fully immune (subscripted by 2). The
R0-values of the sensitive parasites are
and the R0-values of the resistant strains are
Previous models suggested that the parasite with the high-
est  R0 would be the most fit and should predominate
[27,40]. That conclusion always holds when rx = rw, c1 = c2,
and ρ1 = ρ2. However, differences in the drug treatment
rates between clinically immune and nonimmune indi-
viduals can change the result, and it was found that resist-
ant parasites may not spread even when they have the
dominant R0. This can be explained by calculating the
effective reproductive number of the resistant parasite, Rx,
where Rx = R0,xd, and d is the fraction of the population
that can be infected and will transmit the resistant infec-
tion. The effective reproductive number of the resistant
parasite is
Rx = (S1 + S2)((1 - f) R0,x1 + fR0,x2)( 9 )
where f is the fraction of the population that is clinically
immune, and S1 and S2 are the proportion of the popula-
tion that is susceptible and nonimmune, and susceptible
and clinically immune, respectively.
The results suggest that as the transmission rate increases,
the fraction of clinically immune individuals increases,
significantly reducing the effective reproductive number
of the resistant parasite. At certain parameter values it was
even possible for the effective reproductive number of the
resistant parasite to fall below 1 while the reproductive
number of the sensitive parasite remained above 1, effec-
tively abrogating the ability of resistant parasites to spread
(Figure 3). Thus, at higher transmission levels it may be
possible for the resistant parasite to have the dominant R0
but be unable to spread because of the population-wide
level of immunity.
Though the ability of the resistant parasite to spread is not
always compromised, the generalizable result is that at all
levels of fitness cost (including none), it is easier for resist-
ant parasites to spread at lower levels of transmission (Fig-
ure 4). This reduction in the ability of individuals to
transmit the resistant parasite suggests an important
implication: it is relatively easier for resistance to spread in
an area of lower transmission than in an area of higher
transmission. This also helps explain, from an epidemio-
logical perspective, why resistance in general tends to
evolve faster in lower-transmission settings.
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Table 1: Baseline Parameter Values
Acquisition of clinical immunity θ-1 10 years
Loss of clinical immunity γ-1 2 years
Fraction of new infections that are treated and cleared ξ1 0.3
ξ2 0.01
Rate clinical symptoms arise (σi) times Fraction treated (fi) equals rate existing infections are cleared by drugs (ρi) σ1f1 = ρ1 0.025(0.2) = 1/200
σ2f2 = ρ2 0.01(0.2) = 1/500
Disease induced death rate m 180/100000/year
Human feeding rate α 0.3
Infectivity rate b 0.8
Mosquito death rate g 1/10
Number of days required for sporogony n 10
Recovery rate rw 1/(165/b)
rx rw(fitness cost)Malaria Journal 2008, 7:67 http://www.malariajournal.com/content/7/1/67
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Discussion
Simulations of the model found a significant relationship
between malaria immunity and the ability of resistant par-
asites to spread from an initial locus. Previous epidemio-
logical models of malaria transmission assumed that
immune individuals were not infectious; however, the
best available evidence in malaria suggests that immune
individuals remain infectious, though they transmit less
efficiently to mosquitoes [22-24,31] and the frequency
and severity of clinical disease declines [16-19]. Because
they remain infectious but asymptomatically infected,
their relatively lower usage of antimalarials creates a natu-
ral refuge for sensitive parasites, similar to the way non-
transgenic crops act as refugia for Bt-sensitive insects in
agriculture [41]. Increases in the transmission rate result
in concomitant increases in the proportion of clinically
immune individuals, which increases the size of the ref-
uge and reduces the ability of the resistant parasite to
spread. This suggests an epidemiological rationale for the
more likely emergence of resistance in low- or unstable-
transmission settings.
The presence of a refuge of clinically immune individuals
alters the ecological landscape that resistant parasites face,
and introduces a mechanism for the coexistence of resist-
ant and sensitive parasites. Simple models of directly
transmitted infections [40], and a previous model of
malaria transmission [27], suggested there was a critical
threshold level of treatment above which resistance would
fix and below which it would not spread. However, in
those models, there was either no immunity, or immune
individuals were assumed to be noninfectious and were,
therefore, irrelevant for transmission and selection for
Steady state infection level Figure 2
Steady state infection level. The proportion of people 
with P. falciparum infections increases extremely rapidly as 
vectorial capacity increases, but there is a large shift between 
those who are nonimmune and those who are immune. 
Semi-immune individuals mirror the trajectory of total infec-
tions as vectorial capacity increases and quickly become the 
large majority of infections. At low levels of vectorial capac-
ity, the proportion of the population that is clinically immune 
remains extremely low. However, as vectorial capacity 
increases, the proportion of individuals that are clinically 
immune (nonimmune) increases (falls). The clinical incidence 
rate increases sharply at first but then plateaus as the pro-
portion of the population that is clinically immune increases. 
The clinical incidence rate is defined at equilibrium as the 
sum of susceptible individuals who become infected with a 
wild-type phenotype and develop an immediate clinical infec-
tion plus individuals already infected who become sympto-
matic ,  where  i and j are the 
phenotype of the infection and the immune stage, respec-
tively.
hS I s wjj i jj
j i
x +
⎛
⎝
⎜ ⎜
⎞
⎠
⎟ ⎟ ∑ ∑ ,
Immunity reduces resistant parasite fitness Figure 3
Immunity reduces resistant parasite fitness. The clini-
cally immune class influences the ability of a resistant parasite 
to invade. Since individuals in this class do not progress to 
clinical malaria as often, they are treated less often; this cre-
ates a refuge for the wild-type parasites. As vectorial capacity 
increases, the clinically immune class is maintained at higher 
and higher levels until it becomes biologically impossible for 
the resistant parasite to spread. This paradigm exists because 
of the population of clinically immune individuals, without 
whom the resistant parasite would be able to spread at any 
vectorial capacity (as shown by the dashed line above).Malaria Journal 2008, 7:67 http://www.malariajournal.com/content/7/1/67
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resistance. Clinical immunity changes the criteria for
determining the critical threshold so that the fraction of
clinical episodes that are treated, as well as the level of
immunity in the community, which determines the frac-
tion of new infections that result in a clinical episode, are
both important. Therefore, in populations where immu-
nity has developed, the resistant parasite faces a different
fitness landscape; they may not be the most fit, despite
having the highest R0, which can prevent the parasite from
either fixing or spreading. This result also suggests that dif-
ferential treatment levels of host-groups can create differ-
ential ecological niches allowing the resistant and
sensitive parasites to coexist [42].
History of epidemiological models of malaria
There is a striking difference between the findings of this
paper and a previously published epidemiological model
of antimalarial resistance [27]. To explain the differences,
a brief history of malaria models is warranted. A quantita-
tive approach to malaria epidemiology organized around
the parasite life-cycle was first described mathematically
by Ross [43], and later revised by Macdonald to consider
mosquito mortality during sporogony [32,44]. In the
1970s several major innovations in malaria modeling
were first introduced and field-tested during a malaria
control project in the Garki region of Nigeria [35]. The
mathematical model of control developed for the Garki
project considered the clearance of infection in hosts that
have been infected by more than one parasite brood
[20,45], and the development of blood-stage immunity
and transmission-blocking immunity in the human host
[20]. Despite a model that assumed parasite infections
were complex and evidence that gametocytes remain
present throughout life, the Garki model made a simplify-
ing assumption that new infections remained infectious
for a short period of time. Thereafter, infections persisted
until the person either cleared the infection or developed
immunity. The Garki model called this a semi-immune
state. In this semi-immune state, humans could become
re-infected, but they were never infectious. Mathematical
epidemiologists later noted that individuals who were
infected but not infectious were epidemiologically irrele-
vant for transmission, and the Garki model was simplified
into an SIRS compartment model in which the dynamics
of infection in the semi-immune population were
replaced by a recovered and immune state with immune
boosting [25,26]. The SIRS model was a familiar model to
mathematical epidemiologists, and it has been the basis
for many subsequent papers on malaria epidemiology,
but the assumptions about immunity have been propa-
gated and revised without much critical thought.
This paper is an attempt to demonstrate the importance of
immunity in modeling the transmission dynamics of
malaria with respect to the introduction of resistance.
While the implications of the results are significant for
drug policy, it is prudent to note that as with all models a
number of simplifying assumptions have been made. In
incorporating immunity, the process of immunity acqui-
sition has been simplified so that individuals acquire
immunity in a stepwise fashion after 10 years of continu-
ous infection, and they lose immunity after two years of
continuous non-infection. This is a simplification of the
complicated process that is immunity. It ignores age
effects, differences between immune individuals at older
ages and younger ages, and faster acquisition of immu-
nity, which may occur in areas of higher transmission [46]
or after fewer challenges in low transmission areas [47].
While this is a simplification, evidence suggests that it
gives a representation of reality that is close enough to
make qualitative observations [29,30,34,35]. Despite the
simplification of immunity, the basic model (without
resistance) accords well with both field data and other
models of transmission dynamics, and changes in these
values did not change the qualitative results. Thus, the
model, as formulated, likely captures the qualitative dif-
ferences that exist between areas with different transmis-
sion levels, and is, hopefully, only the first step in more
Effective reproductive rate and fitness cost of resistance Figure 4
Effective reproductive rate and fitness cost of resist-
ance. The higher the fitness cost of resistance (1 - rw/rx), the 
lower the absolute level of the effective reproductive 
number. Qualitatively, this suggests an important implication: 
it is always more difficult for the parasite to evolve (i.e., 
emerge and spread) resistance in higher-transmission set-
tings.
-6 -4 -2 0 2 4 6
0
1
2
3
4
Vectorial Capacity
E
f
f
e
c
t
i
v
e
 
R
e
p
r
o
d
u
c
t
i
v
e
 
R
a
t
e
Base
20%
33%
43%
50%
60%Malaria Journal 2008, 7:67 http://www.malariajournal.com/content/7/1/67
Page 8 of 9
(page number not for citation purposes)
detailed modeling of the spread of antimalarial resistance
which takes account of the importance of immunity.
Conclusion
The link between the transmission rate and the probabil-
ity that de novo mutants can both arise and spread is a crit-
ical issue for developing strategies to mitigate resistance
emergence. Though it is impossible to be certain, histori-
cal analysis of the evolution of resistance has suggested
that it originated in low or unstable transmission areas
[2,3]. Quantitative population genetic models have sup-
ported this assertion, suggesting that there may be genetic
reasons why resistance is less likely to evolve in high-
transmission settings [3,9,11,12], but individual models
may not always explain population-level phenomena.
Epidemiological models, which can take account of spe-
cific population characteristics, have been hampered by
the assumption that immune individuals play no qualita-
tive role in the dynamics of transmission. Consequently,
an epidemiological model could not offer an explanation
for why resistance emerged outside Africa [27]. The model
in this paper demonstrates that the existence of a refuge
for drug-sensitive parasites in high-transmission areas can
slow or prevent the evolution of resistance; this has enor-
mous implications for the design of effective malaria con-
trol strategies.
Efforts to control malaria have been undermined by the
emergence of resistance, which now exists to all known
antimalarials except the artemisinin compounds. To help
ensure a longer period of efficacy for artemisinin, the
World Health Organization has proposed a global sub-
sidy to comply with its mandate that all new artemisinin-
based therapies be deployed as combinations [48]. One
concern with this strategy is that increased use in high-
transmission areas may engender resistance at a faster rate.
The results as determined by this model, mitigates that
concern, showing that the existence of a refuge of immune
individuals makes this outcome highly unlikely. How-
ever, in areas with low transmission intensity, the relative
paucity of immune individuals increases the risk that
resistance will emerge. Because the emergence of resist-
ance to an antimalarial in any country threatens the via-
bility of the drug in all countries [49], areas of relatively
lower transmission should be a focus in controlling the
emergence of resistance. As a corollary, eliminating
malaria from areas of low transmission intensity may
have the global benefit of prolonging the effective lifetime
of antimalarial drugs.
Although areas of low transmission should implement
strategies to reduce the likelihood of resistance, high-
transmission areas are also a concern because transmis-
sion intensity is reduced through mass distribution of
insecticide-treated bed nets. The analysis in this paper sug-
gests that among-host selection for resistance increases as
functional immunity wanes and the refuge for drug-sensi-
tive parasites shrinks or disappears. Thus, implementation
of transmission reduction strategies should also include
improved surveillance for drug resistance with resources
to deploy appropriate containment strategies to prevent
the geographical dissemination of resistance.
The intention of this study was to evaluate the qualitative
importance of immunity in the transmission dynamics of
malaria and its role in the development of resistance. Epi-
demiological models of malaria transmission, which can
synthesize various factors about how emergence and
spread are linked to the composition of the population,
can be useful tools in determining optimal drug treatment
strategies to extend the effective life of newly introduced
therapies; however, they must take account of immune
individuals and the refuge they provide for sensitive para-
sites.
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